Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27620900 | 0.84 | L3MBTL1 (0.55) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL5426523 | 0.84 | L3MBTL1 (0.47) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL14292157 | 0.83 | ATM (0.48) | L3MBTL1LMNAHTTKDM4EMAPT | |
| SCHEMBL27937954 | 0.82 | L3MBTL1 (0.46) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL2870268 | 0.81 | L3MBTL1 (0.53) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL27938009 | 0.81 | L3MBTL1 (0.45) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL2137543 | 0.80 | L3MBTL1 (0.56) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL28268501 | 0.80 | L3MBTL1 (0.51) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL10423678 | 0.80 | L3MBTL1 (0.51) | L3MBTL1LMNAHTTDRD3CALM1 | |
| SCHEMBL1506234 | 0.80 | L3MBTL1 (0.56) | L3MBTL1LMNAHTTDRD3CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430036-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086539-A2 | BCAT2 INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-108069957-B | Prolyl hydroxylase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3752510-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | Vertex Pharmaceuticals Incorporated (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2019161078-A1 | MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-3519464-A1 | THIOUREA GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | Dow Global Technologies LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018063799-A1 | THIOUREA GROUP IV TRANSITION METAL CATALYSTS AND POLYMERIZATION SYSTEMS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2780026-A2 | HCV NS3 PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2705028-A1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | Egis Gyógyszergyár Nyilvánosan Müködö Részvény-Társaság (HU) | 2014-03-12 | — | — | EP | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1948670-A1 | METHOD OF SEPARATING ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF APOLAR AMINES | BASF SE (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| WO-2007054392-A1 | METHOD OF SEPARATING ACIDS FROM CHEMICAL REACTION MIXTURES BY MEANS OF APOLAR AMINES | BASF SE (DE) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| EP-1615644-B1 | SUBSTITUTED 4-PHENYL-4-[1H-IMIDAZOL-2-YL]-PIPERIDINE DERIVATIVES AND THEIR USE AS SELECTIVE NON-PEPTIDE DELTA OPIOID AGONISTS WITH ANTIDEPRESSANT AND ANXIOLYTIC ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| CN-1531425-A | Urea derivatives as integrin alpha 4 antagonists | ������ҩ������˾ | 2004-09-22 | — | — | CN | disclosed |
| US-4025467-A | CONVERSION OF COVALENT CHLORINE TO IONIC CHLORIDE | ROHM AND HAAS COMPANY (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | L3MBTL1 4390/4885LMNA 1127/4885HTT 3188/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | L3MBTL1 4390/4885LMNA 1127/4885HTT 3188/4885 |
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | L3MBTL1 3038/4885LMNA 2557/4885HTT 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.